SCHEMBL1490741

SCHEMBL1490741

CCCCCCCCCCCC(CCCCCCCC)OC(=O)C(CC)CCCC

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA2 P00918 7/20 0.59
CA1 P00915 4/20 0.59
MAPK1 P28482 2/20 0.50
ZDHHC7 Q9NXF8 1/20 0.43
FAAH O00519 1/20 0.41
GRIK1 P39086 1/20 0.41
GRIK2 Q13002 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
GPR84 Q9NQS5 3/20 0.40
FFAR1 O14842 1/20 0.40
GAA P10253 1/20 0.40
XBP1 P17861 1/20 0.40
ATM Q13315 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPT P10636 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL535672 1.00 CA2 (0.59) CA2CA1MAPK1ZDHHC7FAAH
SCHEMBL1274961 1.00 CA2 (0.59) CA2CA1MAPK1ZDHHC7FAAH
SCHEMBL28899012 1.00 CA2 (0.59) CA2CA1MAPK1ZDHHC7FAAH
SCHEMBL866148 1.00 CA2 (0.59) CA2CA1MAPK1ZDHHC7FAAH
SCHEMBL22471739 0.98 CA2 (0.56) CA2CA1MAPK1ZDHHC7FAAH
2-Ethylhexanoic Acid SCHEMBL9543013 0.94 CA2 (0.62) CA2CA1MAPK1GRIK1GRIK2
Ether SCHEMBL3957556 0.94 CA2 (0.53) CA2CA1MAPK1ZDHHC7FAAH
SCHEMBL2304371 0.93 CA2 (0.55) CA2CA1MAPK1ZDHHC7FAAH
SCHEMBL473755 0.93 CA2 (0.59) CA2CA1MAPK1ZDHHC7FAAH
SCHEMBL2305289 0.93 CA2 (0.55) CA2CA1MAPK1ZDHHC7FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119015394-A Sulfur-containing compound preparation, and preparation method and application thereof 上海优斐斯生物科技有限公司 2024-11-26 CN claimed
CN-119015394-A Sulfur-containing compound preparation, and preparation method and application thereof 上海优斐斯生物科技有限公司 2024-11-26 CN disclosed
US-11234905-B2 Formulations having improved compatibility with nonwoven substrates KIMBERLY-CLARK WORLDWIDE, INC. (US) 2022-02-01 US disclosed
US-10307351-B2 Substrates having formulations with improved transferability KIMBERLY-CLARK WORLDWIDE, INC. (US) 2019-06-04 US disclosed
EP-2309972-B1 SUBSTRATES HAVING FORMULATIONS WITH IMPROVED TRANSFERABILITY KIMBERLY CLARK CO (US) 2018-10-24 EP disclosed
US-20180200168-A1 SUBSTRATES HAVING FORMULATIONS WITH IMPROVED TRANSFERABILITY KIMBERLY-CLARK WORLDWIDE, INC. 2018-07-19 US disclosed
US-9949906-B2 Substrates having formulations with improved transferability KIMBERLY-CLARK WORLDWIDE, INC. (US) 2018-04-24 US disclosed
EP-2309971-B1 FORMULATIONS HAVING IMPROVED COMPATIBILITY WITH NONWOVEN SUBSTRATES KIMBERLY CLARK CO (US) 2015-10-07 EP disclosed
US-8790710-B1 Topical composition comprising umbilical cord blood serum Novo Solutions, MD, L.L.C. (US) 2014-07-29 US disclosed
US-20120093896-A1 USE OF NANODISPERSIONS TO PROTECT WATER-SOLUBLE INGREDIENTS IN COSMETIC END FORMULATIONS CIBA CORPORATION (US) 2012-04-19 US disclosed
WO-2010004519-A2 SUBSTRATES HAVING FORMULATIONS WITH IMPROVED TRANSFERABILITY KIMBERLY-CLARK WORLDWIDE, INC. (US) 2010-01-14 WO disclosed
WO-2010004518-A2 FORMULATIONS HAVING IMPROVED COMPATIBILITY WITH NONWOVEN SUBSTRATES KIMBERLY-CLARK WORLDWIDE, INC. (US) 2010-01-14 WO disclosed
WO-2010001293-A2 SPRAYABLE SKIN PROTECTANT FORMULATION AND METHOD OF USE KIMBERLY-CLARK WORLDWIDE, INC. (US) 2010-01-07 WO disclosed
US-20090324506-A1 Sprayable skin protectant formulation and method of use KIMBERLY-CLARK WORLDWIDE, INC. 2009-12-31 US disclosed
EP-2099530-A1 UV ABSORBER FORMULATIONS Ciba Holding Inc. (CH) 2009-09-16 EP disclosed
US-20090196894-A1 Self Tanning Composition CIBA CORP. 2009-08-06 US disclosed
EP-2026746-A2 SELF TANNING COMPOSITION Ciba Holding Inc. (CH) 2009-02-25 EP disclosed
WO-2009016064-A1 USE OF NANODISPERSIONS TO PROTECT WATER-SOLUBLE INGREDIENTS IN COSMETIC END FORMULATIONS BASF SE (CH) 2009-02-05 WO disclosed
WO-2008080892-A1 UV ABSORBER FORMULATIONS CIBA HOLDING INC. (CH) 2008-07-10 WO disclosed
WO-2007137958-A2 SELF TANNING COMPOSITION CIBA HOLDING INC. (CH) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090196894-A1 Self Tanning Composition C9, KRT18, F12 CA2 4251/4885CA1 4188/4885MAPK1 2268/4885
US-20120093896-A1 USE OF NANODISPERSIONS TO PROTECT WATER-SOLUBLE INGREDIENTS IN COSMETIC END FORMULATIONS CUTA, PROC, RBP1 CA2 2253/4885CA1 4037/4885MAPK1 3461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.